Expert Interview
Looking at Vigil Neuroscience's VG-3927 for the potential treatment of Alzheimer's Disease
Ticker(s): VIGL, BIIB, LLYInstitution: The Cleveland Clinic
- Assistant Professor of Neurology at Cleveland Clinic
- Manages 10-15 patients with Myasthenia Gravis and 50 patients with progressive multiple sclerosis
- Serves as Director of Inpatient General Neurology and specializes in managing central nervous system inflammatory disorders
Can you provide some background information about yourself, your expertise, and your current practice setting?
How many Alzheimer's patients do you currently see on a monthly basis, and what is your treatment algorithm for Alzheimer's disease?
What are your thoughts on the differences between Leqembi and Kisunla, and which one do you think might be preferable?
What is your level of excitement for VG-3927 as a potential treatment?
Added By: ben_adminCan you discuss the unique mechanism of action of VG-3927 and how it relates to Alzheimer's Disease?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
